# Ranolazine

## Rancad 500mg extended release

| TAH Drug Code      | [ORANC](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ORANC)                                                                                                                                                                                                                                                 |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Stable angina.                                                                                                                                                                                                                                                                                                         |
| Dosing             | Oral: Initial: 500 mg twice daily; may increase to 1000 mg twice daily as needed (based on symptoms); maximum recommended dose: 1000 mg twice daily.                                                                                                                                                                   |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                               |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                               |
| Contraindications  | Concurrent use of CYP3A inducers, such as rifampin, rifabutin, rifapentine, phenobarbital, phenytoin, carbamazepine, and St John's wort. Concurrent use of strong CYP3A inhibitors such as ketoconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, ritonavir, indinavir, and saquinavir. Hepatic cirrhosis |
| Adverse Effects    | Common Gastrointestinal: Constipation (4.5% ), Nausea (4.4% ) Neurologic: Dizziness (6.2% ), Headache (5.5% ) Serious Cardiovascular: Prolonged QT interval, Vasovagal syncope (0.5% to 4% )                                                                                                                           |
| Pregnancy          | No (Limited) Human Data â€“ Animal Data Suggest Risk                                                                                                                                                                                                                                                                     |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                           |
| More Info          | [UpToDate](https://www.uptodate.com/contents/ranolazine-drug-information)                                                                                                                                                                                                                                              |

